Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

Published:2008-05-20 Issue:15_suppl Volume:26 Page:3007-3007
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Sznol M.,Hodi F. S.,Margolin K.,McDermott D. F.,Ernstoff M. S.,Kirkwood J. M.,Wojtaszek C.,Feltquate D.,Logan T.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2008.26.15_suppl.3007

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selenium nanoparticles enhance the anti-tumor immune responses of anti-4-1BB antibody and alleviate the adverse effects on mice;Immunobiology;2024-09

2. Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 ⁺ T cells in cis and in trans;Science Advances;2024-08-23

3. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers;Biomedicine & Pharmacotherapy;2024-02

4. 4-1BB immunotherapy: advances and hurdles;Experimental & Molecular Medicine;2024-01-04

5. Interrogating ligand-receptor interactions using highly sensitive cellular biosensors;Nature Communications;2023-11-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP